NasdaqCM - Nasdaq Real Time Price USD

HOOKIPA Pharma Inc. (HOOK)

1.4200

0.0000

(0.00%)

At close: June 13 at 4:00:01 PM EDT

1.4100

-0.01

(-0.70%)

After hours: June 13 at 7:45:39 PM EDT

Gilead (GILD) to Acquire HOOK for $10 million

Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. GILD is only purchasing HOOK’s antiviral programs, specifically the “HB-400” & “HB-500”. The company first […]

Insider Monkey 21 days ago

HOOK
0.00%

GILD
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS IT FORMS PART

GlobeNewswire 3 months ago

HOOK
0.00%
Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial

HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the United States. The Phase 1b clinical trial is evaluating the safety and tolerability, reactogenicity, and immunogenicity to repeated doses of HB-500 in participants with HIV on suppressive antiretroviral treatment. The Phase 1b design comprises two dose escalation cohorts with participants randomized to recei

TipRanks 4 months ago

HOOK
0.00%
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected H2 2025 NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a cl

GlobeNewswire 4 months ago

HOOK
0.00%
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. For immediate release 10 January 202

GlobeNewswire 4 months ago

HOOK
0.00%
HOOKIPA Pharma Inc - FORM 8 (OPD)

NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) -- FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFERRules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:HOOKIPA Pharma Inc.(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c) Name of offeror/offer

GlobeNewswire 5 months ago

HOOK
0.00%
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements. HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIP

GlobeNewswire 5 months ago

HOOK
0.00%
HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 6 January 2025 HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment NEW YORK and VIENNA, Austria, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The following amendment has been made to the ‘Rule 2.9 Information’ disclosed by HOOKIPA in the Rule 2.4 announcement made on 2 January 2025 regarding the

GlobeNewswire 5 months ago

HOOK
0.00%
Hookipa Pharma, Poolberg Pharma in Discussions for All-Stock Merger

Hookipa Pharma (HOOK) and Poolbeg Pharma said Thursday that they have entered into non-binding discu

PREMIUM
MT Newswires 5 months ago

HOOK
0.00%

POLBF
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”) AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE.THIS ANNOUNCEMENT CONSTITUTES INSIDE IN

GlobeNewswire 5 months ago

HOOK
0.00%
Hookipa Pharma price target lowered to $7 from $24 at JMP Securities

JMP Securities lowered the firm’s price target on Hookipa Pharma (HOOK) to $7 from $24 and keeps an Outperform rating on the shares. Hookipa announced Wednesday that it will reduce its workforce by about 80% starting this quarter and pause the eseba-vec cancer vaccine program in HPV16+ head-and-neck cancer, including an early termination of the Phase 1/2, not due to efficacy or safety, looking instead to partner the program, the analyst tells investors in a research note. The firm has removed es

TipRanks 6 months ago

HOOK
0.00%
Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program

In a regulatory filing on Wednesday, Hookipa Pharma (HOOK) announced that on November 18, the company approved a plan to continue to improve its cost structure and operating efficiency, which includes a reduction in the company’s workforce by approximately 80% of the company’s then-current employee base. The company expects to begin the implementation of the Restructuring Plan in the fourth quarter of 2024 and expects the Restructuring Plan to be substantially completed by the end of the first h

TipRanks 6 months ago

GILD

HOOK
0.00%
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 6 months ago

HOOK
0.00%
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

HOOKIPA Pharma ( NASDAQ:HOOK ) Third Quarter 2024 Results Key Financial Results Revenue: US$4.70m (down 32% from 3Q...

Simply Wall St. 6 months ago

HOOK
0.00%
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset pres

GlobeNewswire 6 months ago

HOOK
0.00%
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker

Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safetyNEW YORK and VIENNA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today

GlobeNewswire 6 months ago

HOOK
0.00%
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that updated Phase 2 data for eseba-vec (HB200) plus pem

GlobeNewswire 7 months ago

HOOK
0.00%
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service IIT will evaluate eseba-vec in patients who are HPV16+ after treatment for curative intent Potential to expand the eseba-vec HNSCC opportunity into adjuvant care Initial safety and efficacy data from IIT expected in 2026 NEW YORK and VIENNA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or th

GlobeNewswire 7 months ago

HOOK
0.00%
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS

GlobeNewswire 8 months ago

HOOK
0.00%
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet

The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 9 months ago

HOOK
0.00%

Performance Overview

Return	HOOK	S&P 500 (^GSPC)
YTD	-29.35%	+1.62%
1-Year	-81.84%	+10.00%
3-Year	-91.45%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

HOOKIPA Pharma Inc. (HOOK)

Gilead (GILD) to Acquire HOOK for $10 million

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

HOOKIPA Pharma Inc - FORM 8 (OPD)

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Hookipa Pharma, Poolberg Pharma in Discussions for All-Stock Merger

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

Hookipa Pharma price target lowered to $7 from $24 at JMP Securities

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet

Performance Overview